Hepatic Steatosis Index (HSI): A Valuable Biomarker in Subjects with Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)

IF 3.7 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Annals of hepatology Pub Date : 2024-02-01 DOI:10.1016/j.aohep.2024.101391

Bryan A. Priego-Parra , Arturo Triana-Romero , Génesis P. Martínez-Pérez , Sara A. Reyes-Diaz , Héctor R. Ordaz-Alvarez , Raúl Bernal-Reyes , María E. Icaza-Chávez , Sophia E. Martínez-Vázquez , Ana D. Cano-Contreras , Héctor Vivanco-Cid , José M. Remes-Troche

{"title":"Hepatic Steatosis Index (HSI): A Valuable Biomarker in Subjects with Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)","authors":"Bryan A. Priego-Parra , Arturo Triana-Romero , Génesis P. Martínez-Pérez , Sara A. Reyes-Diaz , Héctor R. Ordaz-Alvarez , Raúl Bernal-Reyes , María E. Icaza-Chávez , Sophia E. Martínez-Vázquez , Ana D. Cano-Contreras , Héctor Vivanco-Cid , José M. Remes-Troche","doi":"10.1016/j.aohep.2024.101391","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction and Objectives</h3><p>Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) has been recognized as the hepatic component of metabolic syndrome and has become a growing public health concern. Early and accurate detection of MAFLD is crucial for implementing appropriate intervention strategies and preventing progression to serious complications such as liver cirrhosis. We aimed to describe the diagnostic performance of the Hepatic Steatosis Index (HSI) in subjects with MAFLD and compare it with the Homeostatic Model Assessment of Insulin Resistance (HOMA), Waist-to-Hip Ratio (WHR), and Visceral Fat (SECA).</p></div><div><h3>Materials and Methods</h3><p>Retrospective design study. Bioanthropometric, clinical, and biochemical variables were collected. The HSI was calculated using the formula HSI = 8 * ALT/AST + BMI + 2 (if diabetic) + 2 (if female). ROC curves and their areas were generated. Statistical significance was determined at p < 0.05.</p></div><div><h3>Results</h3><p>A total of 585 subjects were evaluated, of whom 279 were classified with MAFLD (65.5% females) and 306 without MAFLD (76.8% females). Subjects with MAFLD exhibited higher values of age, BMI, WHR, HOMA, CAP, and HSI (Table 1). The HSI showed a diagnostic performance with an area under the curve (AUC) of 0.80. A cutoff point of 39.9 was established for the HSI, with a sensitivity of 63%, specificity of 74%, positive predictive value (PPV) of 73%, and negative predictive value (NPV) of 64%. The HSI demonstrated superior diagnostic performance compared to visceral fat (0.70), HOMA (0.70), and WHR (0.66) (Fig 1).</p></div><div><h3>Conclusions</h3><p>The results of this study demonstrate that HOMA, visceral fat, and ICC can be useful as screening strategies in MAFLD. However, the Hepatic Steatosis Index (HSI) showed superior diagnostic performance compared to the other evaluated biomarkers. Therefore, it is suggested that HSI be considered a useful diagnostic tool in MAFLD.</p></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":null,"pages":null},"PeriodicalIF":3.7000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1665268124001856/pdfft?md5=83c8d94062c8b4641ab15ecc282f8aeb&pid=1-s2.0-S1665268124001856-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of hepatology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1665268124001856","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction and Objectives

Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) has been recognized as the hepatic component of metabolic syndrome and has become a growing public health concern. Early and accurate detection of MAFLD is crucial for implementing appropriate intervention strategies and preventing progression to serious complications such as liver cirrhosis. We aimed to describe the diagnostic performance of the Hepatic Steatosis Index (HSI) in subjects with MAFLD and compare it with the Homeostatic Model Assessment of Insulin Resistance (HOMA), Waist-to-Hip Ratio (WHR), and Visceral Fat (SECA).

Materials and Methods

Retrospective design study. Bioanthropometric, clinical, and biochemical variables were collected. The HSI was calculated using the formula HSI = 8 * ALT/AST + BMI + 2 (if diabetic) + 2 (if female). ROC curves and their areas were generated. Statistical significance was determined at p < 0.05.

Results

A total of 585 subjects were evaluated, of whom 279 were classified with MAFLD (65.5% females) and 306 without MAFLD (76.8% females). Subjects with MAFLD exhibited higher values of age, BMI, WHR, HOMA, CAP, and HSI (Table 1). The HSI showed a diagnostic performance with an area under the curve (AUC) of 0.80. A cutoff point of 39.9 was established for the HSI, with a sensitivity of 63%, specificity of 74%, positive predictive value (PPV) of 73%, and negative predictive value (NPV) of 64%. The HSI demonstrated superior diagnostic performance compared to visceral fat (0.70), HOMA (0.70), and WHR (0.66) (Fig 1).

Conclusions

The results of this study demonstrate that HOMA, visceral fat, and ICC can be useful as screening strategies in MAFLD. However, the Hepatic Steatosis Index (HSI) showed superior diagnostic performance compared to the other evaluated biomarkers. Therefore, it is suggested that HSI be considered a useful diagnostic tool in MAFLD.

查看原文本刊更多论文

肝脏脂肪变性指数（HSI）：代谢功能障碍相关性脂肪肝（MAFLD）患者的重要生物标志物

简介和目的代谢功能障碍相关性脂肪肝（MAFLD）已被认为是代谢综合征的肝脏组成部分，并已成为一个日益受到关注的公共卫生问题。早期准确地检测出 MAFLD 对实施适当的干预策略和防止发展为肝硬化等严重并发症至关重要。我们旨在描述肝脏脂肪变性指数（HSI）在 MAFLD 患者中的诊断性能，并将其与胰岛素抵抗自律模型评估（HOMA）、腰臀比（WHR）和内脏脂肪（SECA）进行比较。收集了生物人类计量学、临床和生化变量。使用公式 HSI = 8 * ALT/AST + BMI + 2（如果有糖尿病）+ 2（如果是女性）计算 HSI。生成 ROC 曲线及其面积。结果共评估了 585 名受试者，其中 279 人被归类为 MAFLD（女性占 65.5%），306 人未被归类为 MAFLD（女性占 76.8%）。MAFLD受试者的年龄、体重指数、WHR、HOMA、CAP和HSI值均较高（表1）。HSI 的曲线下面积（AUC）为 0.80，显示出良好的诊断性能。HSI 的临界点为 39.9，灵敏度为 63%，特异性为 74%，阳性预测值 (PPV) 为 73%，阴性预测值 (NPV) 为 64%。与内脏脂肪（0.70）、HOMA（0.70）和 WHR（0.66）相比，肝脏脂肪变异指数显示出更优越的诊断性能（图 1）。然而，与其他评估的生物标志物相比，肝脏脂肪变性指数（HSI）显示出更优越的诊断性能。因此，建议将 HSI 作为 MAFLD 的有用诊断工具。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of hepatology 医学-胃肠肝病学

CiteScore

7.90

自引率

2.60%

发文量

183

审稿时长

4-8 weeks

期刊介绍： Annals of Hepatology publishes original research on the biology and diseases of the liver in both humans and experimental models. Contributions may be submitted as regular articles. The journal also publishes concise reviews of both basic and clinical topics.